|
|
| This article has multiple issues. Please help improve it or discuss these issues on the talk page. |
|
|
|
Mesoblast Limited is an Australian-based regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease and back pain. The company is headed by Silviu Itescu, who founded the company in 2004.[1]
Contents
- 1 Mesenchymal lineage cells
- 2 Use
- 3 Medical problems
- 3.1 Back pain
- 3.2 Congestive heart failure
- 3.3 Graft-versus-host disease
- 3.4 Crohn's disease
- 4 Research and development
- 4.1 Back pain
- 4.2 2011
- 4.3 2014
- 4.4 2015
- 4.5 Crohn's disease
- 4.6 Graft versus host disease
- 4.7 Diabetic nephropathy
- 5 Acquisitions and manufacturing
- 6 Financial performance
- 7 References
Mesenchymal lineage cells
The company is developing a range of regenerative products derived from its proprietary mesenchymal lineage cells.[2] This includes Mesenchymal Precursor Cells (MPCs) and Mesenchymal Stem Cells (MSCs).
Use
Highly purified and immunoselected MPCs and the culture expanded MSCs give rise to secrete trophic factors that then exert multiple mechanisms of action. Mesenchymal lineage precursors have the ability to detect injury and inflammation and respond to local stimuli and signals from the injured tissue by releasing a wide range of biomolecules (growth factors, chemokines, enzymes etc.) that induce the body’s own tissue to grow and regenerate, effectively repairing the injury. Which specific factors are released by the mesenchymal precursors in any given tissue presumably depends on the signals they encounter from the damaged tissue itself.[3] For example, with back pain, the MPCs are injected into the damaged disc in order to regenerate it.[4] Much like a tire jack, it re-inflates the degenerated disc to provide the spine the stability and flexibility it once had.
Medical problems
Back pain
Back pain is the number one cause of disability worldwide.[5] In the United States alone, there are over 6 million patients suffering from chronic back pain that has persisted for three months or more. In 2010, the CDC's National Center for Health Statistics reported that low back pain was the leading cause of pain, affecting 28% of American adults. The United States lifetime prevalence of low back pain is estimated to be at least 60-84%. The total costs of low back pain are estimated to be between $100 billion and $200 billion annually, two thirds of which are due to decreased wages and productivity.[6] Current treatments include physical therapy, steroid injections, light exercise, massage and pain killers. If those treatments fail, then potentially invasive and costly surgery is usually recommended, but not always successful.
Congestive heart failure
According to the Center for Disease Control and Prevention, about 5.1 million people in the United States have heart failure. Approximately half of people who develop heart failure die within five years of diagnosis. In addition, it is estimated that heart failure costs the U.S. $32 billion each year. This includes the cost of medications, health care services and lost productivity at work.[7]
Graft-versus-host disease
Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body.[8]
Crohn's disease
Crohn's disease is a chronic inflammation of the digestive track. This includes the mouth, esophagus, small intestine, large intestine, stomach, rectum and anus. Treatment may include a combination of drugs, nutrition supplements, and surgery. The goals of treatment are to ease the symptoms, control inflammation and improve nutrition. Currently, there is no cure for Crohn's disease. However, people can have a long period of remission where they are symptom free. Drugs may include anti-inflammation, steroids, cortisone, immune system suppressors, Remicade, antibiotics, anti-diarrheal and fluid replacements.[9]
Research and development
Mesoblast seeks to treat ailments in four major areas.[10]
- Immunologic and inflammatory – Cells are administered intravenously to impart immuno-modulatory effects.
- Cardiac and vascular – Cells are administered locally with the aim of improving heart anatomy and function.
- Orthopedic diseases of the spine – Cells are locally administered to potentially repair intervertebral discs or generate new bone
- Oncology - Improving outcomes of bone marrow transplantation in patients with cancer or genetic diseases.
Back pain
Mesoblast’s investigational product candidate MPC-06-ID is being developed to target the population of patients suffering from moderate to severe chronic low back pain due to moderately degenerated discs.[11]
2011
On June 29, 2011, Mesoblast announced that it received clearance from the Food and Drug Administration to begin a Phase 2 trial with its MPC cells for treatment of disc degenerative disease.[12] This trial is primarily designed to assess the safety and efficacy of the cells.
2014
In January 2014, Mesoblast announced positive results of the Phase 2 trial for back pain treatment. It included 100 patients with moderate to severe back pain that were evaluated in a randomized, placebo controlled study. Patients were treated across 13 sites in the US and Australia. The results showed that 69% of patients given a 6 million dose of MPCs and 62% given an 18 million dose experienced a more than 50% reduction in low back pain at 12 months. This compares to around 35% for the controls. Patients underwent the outpatient injection for a single painful degenerated lumbar level and are being evaluated for safety and efficacy over a total of 36 months to evaluate long-term treatment effects.[13] Other key findings included improvements in function and disc stability.
The participating sites were Arizona Pain Specialists, UC Davis Spine Center, The Spine Institute, IPM Medical Group, Inc., Denver Spine, Rocky Mountain Associates in Orthopedic Medicine, P.C., Emory University School of Medicine, Carolina Neurosurgery and Spine Associates, Central Texas Spine Institute, Richmond Bone and Joint Clinic, Memorial Hermann Medical Group, Washington Center for Pain Management, The Center for Pain Relief, Inc. and Monash Medical Center of Victoria, Australia.[14] Mesoblast CEO Silviu Itescu said the company would then plan to meet with regulators in major jurisdictions across the U.S. to discuss product registration.
In August 2014, Mesoblast announced in its 2014 results and corporate strategy that the Food and Drug Administration granted approval to advance to an MPC Phase 3 trial for chronic lower back pain. Phase 3 will begin before the end of 2014.[15] Mesoblast CEO Silviu Itescu estimated Phase 3 completion within 2–3 years, meaning sometime in late 2016 or 2017.[16] Based on the FDA's processing time, MPC cells for back pain are projected to be commercially available between 2019 and 2022.[17]
In November 2014, in Japan, the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act (PMD Act) took effect. This Act established a pathway for expedited approval in Japan for regenerative medical products. Japan’s new policy requires an early stage clinical trial (i.e. Phase I or small Phase II) at the minimum to confirm safety of the therapy and provide evidence of efficacy. Rather than requiring that the therapy then be evaluated in subsequent trials before making it available to patients, Japan’s new law will allow for a “conditional approval” enabling the product to be brought to market, and for the product to obtain reimbursement in an accelerated manner. Conditional approval does not mean that the regulatory approval process is over. It simply allows the therapy to be made available to patients earlier in the process, and for the sponsor company to begin commercialization and obtain reimbursement. [18] As a result, Mesoblast announced they would leverage existing Phase 2 clinical trial results for Tier 1 and Tier 2 product candidates. Tier 1 includes MPC cells for back pain.[19] Conditional approval would last seven years.[20]
2015
On January 14, 2015, Mesoblast confirmed Phase 3 had already begun. The company also provided projected timeframes. Mesoblast anticipates patient enrollment completion in mid-2016, an interim analysis in mid-2016 and top-line data in mid-2017.[21] The objective of the Phase 3 clinical program will be to confirm the positive outcomes seen in the Company’s Phase 2 clinical trial where product candidate, MPC-06-ID, demonstrated the potential to provide durable improvement in pain and function for patients who suffer with CDLBP due to degenerative disc disease. The primary endpoint in the Phase 3 program will seek to confirm the treatment benefit seen in Phase 2 for MPC-06-ID against saline control using a composite of durable improvement in pain and function.[11]
On February 10, 2015, Mesoblast was granted a key patent by the United States Patent and Trademark Office (USPTO) covering its proprietary Mesenchymal Precursor Cell (MPC) technology for use in the treatment of degenerated intervertebral discs. Granted US patent number 8,858,932 provides Mesoblast with exclusive commercial rights through to June 2029. There is also potential for patent term and regulatory exclusivity extensions which would provide longer term protection.[11]
On March 19, 2015, Mesoblast announced that it has been selected by the Japan External Trade Organization (JETRO) as the only regenerative medicine company worldwide to receive fast track access to potential investment incentives across all levels of government in Japan. Mesoblast will receive a specially tailored market and government incentive roadmap aimed at providing a more attractive business environment. Mesoblast Chief Executive Silviu Itescu welcomed the recognition from the Japanese Government. “Japan is a major market for our cell-based therapeutics and offers near-term potential for product approvals and revenues. The selection of Mesoblast by JETRO as the only regenerative medicine company to receive investment priority status will guide the strategic direction of our commercial plans in Japan, in conjunction with our current and future strategic partners.”[22]
On April 8, 2015, Mesoblast announced it intended to expand the Phase 3 clinical program of its product candidate MPC-06-ID in the treatment of chronic low back pain due to degenerative disc disease to include sites in the European Union (EU). This announcement came shortly after a positive meeting with the European Medicines Agency (EMA). The discussions with EMA occurred as part of combined scientific and reimbursement advice under an EU pilot program known as Shaping European Early Dialogues (SEED). The SEED pilot program was established to facilitate early dialogue between EMA, European Health Technology Assessment (HTA) reimbursement bodies, and selected companies with late-stage clinical development programs. Mesoblast's product candidate MPC-06-ID is one of only seven medicines accepted for the SEED program.[23]
Crohn's disease
A Phase 3 multi-centered, double-blind, randomized, placebo-controlled trial is evaluating the safety and efficacy of Prochymal® in moderate to severe Crohn's Disease in patients who are resistant to traditional treatments. Preliminary data from two interim analyses planned under the protocol provided encouraging results. The Phase 3 trial is ongoing.[24]
Graft versus host disease
On September 30, 2014, Mesoblast announced that its Japanese partner, JCR Pharmaceuticals Co Ltd (JCR), filed with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to receive approval for manufacturing, marketing, and product registration of the allogeneic or "off-the-shelf" Mesenchymal Stem Cell (MSC) product JR-031 for the treatment of acute graft versus host disease (GVHD) in children and adults.[25] Mesoblast plans to file production registration with the U.S. FDA in 2016 and will commercially launch the product in New Zealand and Canada in 2016.
Diabetic nephropathy
On June 9, 2015, Mesoblast announced results from the Company's Phase 2 trial in patients with diabetic nephropathy showed that a single infusion of its intravenously delivered allogeneic mesenchymal precursor cell (MPC) product candidate MPC-300-IV was safe, reduced damaging inflammation, and preserved or improved renal function over at least 24 weeks. The results were presented at the late-breaking scientific sessions of the 75th annual meeting of the American Diabetes Association (ADA) currently being held in Boston. The ADA annual meeting brings together approximately 14,000 participants, including clinicians and researchers from 124 countries. [26]
Acquisitions and manufacturing
In December 2010, Mesoblast entered an agreement with US-based Cephalon to develop and commercialize novel adult Mesenchymal Precursor Stem Cell (MPC) therapeutics for degenerative conditions of the cardiovascular and central nervous systems.[27]
In September 2011, Mesoblast entered an agreement with Swiss-based Lonza Group. Under the agreement Lonza will manufacture the stem cells in sufficient quantity to meet the global demand for Mesoblast’s MPC cell products. Mesoblast will also have exclusive access to Lonza’s Cell Therapy facilities in Singapore for the manufacture of allogeneic cell therapy, subject to certain exceptions.[28]
In October 2013, Mesoblast acquired the entire culture-expanded mesenchymal stem cell (MSC) business of Osiris Therapeutics. Cost savings and other synergies are expected across personnel, capital expenditure, and manufacturing.[29] As a result of this acquisition, Mesoblast also inherited a relationship with Japan-based JCR Pharmaceuticals Co. Ltd.[30]
In May 2014, Mesoblast announced it would receive incentives from the Singapore Economic Development Board (EDB) for activities in Singapore related to manufacturing operations, as well as product development and commercialization.[31]
Financial performance
Mesoblast is listed as MSB on the Australian Stock Exchange (ASE).
The company reported its financial results in August 2014:[15]
- Cash reserves of $196.4 million at 30 June 2014
- Net loss after tax increased by $19.3 million (31.3%) to $81.0 million as a result of increased investment in clinical development, commercial manufacturing and investment in employees
- Normalized cash burn for 2014 was $78.2 million compared with $61.9 for 2013
- In addition, total cash outflows included an investment of $35.6 million for the acquisition of the culture-expanded Mesenchymal Stem Cell assets of Osiris Therapeutics Inc.
References
- ^ "BRW Rich 200 list 2014: 136. Silviu Itescu". BRW. Retrieved 13 June 2015.
- ^ http://www.theaustralian.com.au/business/the-deal-magazine/ondek-mesoblast-and-sirtex-investors-roll-the-biotech-dice/story-e6frgabx-1227090406491?nk=3e172135863d3fb12cd9774780650fcb
- ^ Mesoblast. "Mesenchymal Precursor Cell Mechanism of Action - Mesoblast Ltd.". Mesoblast.
- ^ "Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain".
- ^ "Low Back Pain Leading Cause of Disability Worldwide: Study – WebMD". webmd.com.
- ^ Mesoblast. "MESOBLAST REPORTS POSITIVE INTERIM RESULTS IN PHASE 2 TRIAL OF PROPRIETARY ADULT STEM CELLS FOR INTERVERTEBRAL DISC REPAIR". GlobeNewswire News Room.
- ^ "Heart Failure Fact Sheet".
- ^ "Graft-versus-host disease".
- ^ "Crohn's Disease symptoms, facts, statistics, causes, treatment options, outlook.".
- ^ Mesoblast. "Product Pipeline Overview". Mesoblast.
- ^ a b c "News Announcements". Mesoblast.
- ^ "irasia.com - Mesoblast Limited".
- ^ "Mesoblast's MPCs reduce back pain in phase II trial :: Industry News :: Lab+Life Scientist".
- ^ "Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain". clinicaltrials.gov.
- ^ a b "Mesoblast Unveils Path to Bring Its Key Products to Market". Yahoo Finance. 26 August 2014.
- ^ "Ceo Interview No.2 with Mesoblast's Silviu Itescu". YouTube.
- ^ "FDA Drug Approval Process Infographic (Horizontal)".
- ^ "Free SEC Filings Email Alerts - SECFilings.com". secfilings.com. Retrieved 13 June 2015.
- ^ Mesoblast. "Mesoblast Unveils Path to Bring Its Key Products to Market". GlobeNewswire News Room. Retrieved 13 June 2015.
- ^ "Japan Gives a Hug to the Cell Therapy Industry: R. Lee Buckler". thelifesciencesreport.com. Retrieved 13 June 2015.
- ^ "Print - Mesoblast Reports Positive 24 Month Results in Phase 2 Trial for Chronic Low Back Pain and Initiation of Phase 3 Program at JP Morgan Healthcare Conference". globenewswire.com.
- ^ Christine Bennett. "Home - Mesoblast Ltd.". Mesoblast. Retrieved 13 June 2015.
- ^ "News Announcements". Mesoblast. Retrieved 13 June 2015.
- ^ Mesoblast. "Crohn’s Disease". Mesoblast.
- ^ "Mesoblast Partner JCR Pharmaceuticals Files for Marketing Approval of the First Allogeneic Stem Cell Product in Japan". NASDAQ.com.
- ^ http://ir.mesoblast.com/DownloadFile.axd?file=/Report/ComNews/20150609/01631584.pdf
- ^ Cephalon, Inc.; Mesoblast Limited (7 December 2010). "Cephalon and Mesoblast Enter Into Strategic Alliance to Develop... -- FRAZER, Pa. and MELBOURNE, Australia, Dec. 7, 2010 /PRNewswire-FirstCall/ --".
- ^ "Mesoblast and Lonza partner to mass-produce stem cells".
- ^ "MESOBLAST ACQUIRES OSIRIS' CULTURE EXPANDED STEM CELL THERAPEUTIC BUSINESS". FierceBiotech.
- ^ "Japan Gives a Hug to the Cell Therapy Industry: R. Lee Buckler".
- ^ Mesoblast. "Mesoblast Accelerates Plans For Commercialization Manufacturing Operations In Singapore". GlobeNewswire News Room.
